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The purpose was to investigate the association between serum osteoprotegerin (OPG) and risk 
of incident cancer and cancer mortality in a general population. OPG was measured in serum 
collected from 6279 subjects without prior cancer recruited from a general population. 
Incident cancer and cancer-related mortality were registered from inclusion in 1994-95 until 
end of follow-up December 31, 2008. Cox regression models were used to estimate crude and 
adjusted (for age, sex and other confounders) hazard ratios and 95% confidence intervals 
(HR; 95% CI).  There were 948 incident cancers and 387 deaths in the cohort during 71902 
person-years of follow up (median 13.5 years).  Subjects with serum OPG in the upper tertile 
had 79% higher risk of incident gastrointestinal cancer than those in the lowest tertile (HR 
1.79, 95% CI 1.19-2.67). In women < 60 years, serum OPG (per SD 0.81 ng/ml) was 
associated with reduced risk of incident cancer (all cancers merged) (0.73; 0.57-0.94) and 
breast cancer (0.51; 0.31-0.83) after adjustment. Subjects in the upper tertile of OPG had 
higher risk of cancer-related mortality (1.63; 1.16-2.28), particularly mortality from cancer in 
the gastrointestinal system (2.28; 1.21-4.28) compared to those in the lowest OPG tertile.  No 
significant association was detected between OPG and risk of death from cancer in the 
respiratory system or death from prostatic cancer.  Our findings from a large population based 
cohort study suggest that serum OPG was associated with increased risk of incident 
gastrointestinal cancer, inversely associated with breast cancer, and predicts cancer-related 
mortality.  




Osteoprotegerin (OPG) is a member of the tumor necrosis factor (TNF) receptor superfamily 
which exerts its function as a decoy receptor for receptor activator of nuclear factor kappa β 
ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL) (1, 2).  OPG inhibits 
ligation of RANKL and TRAIL to their cognate receptors, and thereby takes part in regulation 
of cell survival (2),  bone homeostasis (3)  and modulation of the immune system (4).   
Experimental studies support the concept that OPG alone and its modulation of RANKL and 
TRAIL may affect risk of cancer.  OPG synthesized by monocytes within tumors may 
promote survival of several tumor cell types (5-7), and in vitro studies indicate that OPG may 
act as a survival factor for tumor cells in both solid tumors (5, 8) and hematological 
malignancies (7), and induce angiogenesis (9, 10).  TRAIL induces apoptosis in a variety of 
cells, and tumor cells are more sensitive than non-malignant cells (9, 11, 12), whereas 
RANKL is involved  in development and metastasis of  breast cancer (13-15). 
Recently, we reported that serum levels of OPG were associated with mortality of ischemic 
heart disease, stroke, and non-vascular causes (16).  The latter finding may indicate that OPG 
is also a marker for other diseases as well as cardiovascular disease in the general population.  
Our observation that increasing serum OPG predicted mortality of non-vascular causes along 
with experimental evidence for a role of OPG-TRAIL-RANKL in carcinogenesis, elicited the 
hypothesis that serum levels of OPG may be positively associated with future risk of cancer 
and cancer-related mortality.  To address this question, we investigated the association 
between serum OPG and future incident cancer and cancer-related mortality in a large 








Participants were recruited from the fourth survey of the Tromsø Study conducted in 1994-95, 
a single-centre prospective, population-based study, with repeated health surveys of 
inhabitants in Tromsø, Norway. All inhabitants aged 55-74 years and 5-10% samples in other 
5-year age groups (25-54 years and 75-85 years) were invited to take part, and 78% (n=6899) 
of invited subjects attended.  Subjects with cancer prior to baseline (n=356) or incident cancer 
within 12 months after baseline (n=72) were excluded to ensure that the presence of cancer or 
occult cancer would not affect levels of serum OPG. Further, subjects were excluded due to 
lack of consent to contribute to research (n=57), not officially registered as inhabitants of the 
municipality of Tromsø (n=12), lack of serum samples for OPG measurement (n=77), and 
development of malignant skin tumors during the follow up period (n=46). Thus, 6279 
subjects were included in our cohort study. Informed written consent was obtained from all 
participants, and the study was approved by the regional committee for research ethics.  
Incident cases of cancer and deaths from cancer among the participants were recorded from 
the date of enrolment through the end of follow-up, December 31st, 2008 and December 31st, 
2007, respectively.  
 
Medical History, Blood Collection and Measurements 
Information on study participants was obtained by a self-administrated questionnaire, 
anthropometric measurements, and measurements of non-fasting blood samples (17).  In brief, 
blood samples were collected from an antecubital vein and serum prepared by centrifugation 
after one hour respite at room temperature.  OPG concentrations were analysed in freshly-
thawed serum aliquots stored at -70°C for 12 years by an ELISA assay (R&D Systems, 
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Abingdon, UK) with mouse anti-human OPG as capture antibody.  Biotinylated goat anti-
human OPG and streptavidin horseradish peroxydase were used for detection. The OPG assay 
was performed according to the instructions by the manufacturer. The intra- and interassay 
coefficients of variation in our laboratory were 6.5% and 9.3%, respectively. Between-assays 
variations in OPG were adjusted for by use of an internal standard.  All samples were 
analyzed in duplicate and the mean value is used in this report.  Serum lipids (total and HDL 
cholesterol, and triglycerides), haemoglobin A1c (HbA1c), high sensitivity C-reactive protein 
(hs-CRP) and creatinine were assessed as previously described (17). 
End point Assessment 
The national 11-digit identification number allowed linkage to the national registry of cancer 
and local diagnosis registries. Information on incident cancer during follow-up, e.g. date of 
cancer diagnosis and location of malignancy (ICD-7 codes 140-205), excluding non-
melanoma skin cancer (ICD-7 191.0-191.9), was obtained from the Cancer Registry of 
Norway (CRN). In a recent evaluation of the data quality, completeness of reporting was 
estimated to 98.8%, whereas organ specific morphology had 94% accuracy (18). Further, 
linkage to the National Causes of Death Registry at Statistics Norway and information from 
the death certificates was used to collect relevant information of the event.  The Norwegian 
Registry of Vital Statistics provided information on emigration and death.  
 
Statistical Methods 
Continuous variables were presented as means (95% confidence interval, or standard 
deviation (SD)), and categorical data as number or percentage. Multivariable linear or logistic 
regression models were used for sex and age adjustment, and to test for linear trends across 
tertiles of OPG for continuous and binary data, respectively. For each participant, person 
years of follow-up were calculated from the date of blood sampling in 1994-95, until the date 
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of an event, the date the participant moved from the municipality of Tromsø, died, or until the 
end of the study period.  Cox-proportional hazard regression models were used to estimate 
hazard ratios (HR), with 95% confidence intervals (CI) for incident cancer, subtypes of cancer   
and cancer-related mortality in the entire population and in analyses stratified for sex and  age 
categories (<60 and ≥60 years).  OPG was treated as both categorized (tertiles) and 
continuous variable in the analyses. Crude analyses, analyses adjusted for age and sex (model 
1), and multivariable analyses with variables shown to be associated with OPG (model 2: 
smoking, BMI, systolic blood pressure, HDL cholesterol, hsCRP, and self-reported diabetes 
mellitus/ HbA1c>6.1%; model 3: model 2 + history of ischemic stroke or myocardial 
infarction) were carried out.  Possible two way interactions between sex, or age, with OPG 
was assessed by including cross product terms to the proportional hazards models. The 
proportional hazard assumption was verified by evaluating the parallelism between the curves 
of the log-log survivor function for tertiles of OPG.  Subjects with incomplete data for the 
assessed covariates were excluded from the multivariable models.  The statistical analyses 
were performed using SPSS software for Windows, version 18.0 (SPSS, Inc., Chicago, IL). 






The study population consisted of 50.5 % (n=3174) women aged 61±10 years with mean 
serum OPG concentration of 3.40±1.06 ng/mL, and 49.5% (n=3105) men aged 60±10 years 
with mean serum OPG concentration of 3.21±1.17 ng/mL (P for sex difference < 0.0001). 
Characteristics of participants at baseline (1994-95) across tertiles of serum OPG are shown in 
table 1.  Age, blood pressure, HDL cholesterol, HbA1c, hsCRP, the proportion of women and 
subjects with diabetes mellitus increased, whereas body mass index (BMI) and triglycerides 
decreased significantly across tertiles of serum OPG.    
There were 948 incident cases of cancer during a total of 71902 person-years of follow-up 
(median 13.5 years). The overall crude cancer incidence rate per 1000 person-years was 13.2 
(95% CI 12.4-14.1) in the total population, 9.9 (95% CI 8.9-11.0) in women, and 16.8 (95% 
CI 15.5-18.2) in men. The organ distribution of the most common cancers across tertiles of 
serum OPG is shown in table 2.  The overall relative risk of incident cancer was 1.06 (95% CI 
0.99-1.15) per 1 SD (1.12 ng/mL) increase in serum OPG in age- and sex-adjusted analysis 
and 1.02 (0.94-1.12) in the multivariable adjusted model (model 3) (Table 3).  Accordingly, 
there was no apparent change in risk estimates across tertiles of serum OPG (p for trend 
=0.70).  Similar findings occurred in analyses stratified for sex.   
Stratification for sex and age (< 60 yrs and ≥ 60 yrs) revealed an inverse relation between 
serum OPG and incident cancer in women below 60 yrs of age (appendix table 1).   The 
relative risk of cancer was 0.73 (95% CI 0.57-0.94) per 1 SD (0.81 ng/ml) increase in serum 
OPG, whereas women in the upper tertile of serum OPG (≥ 3.08 ng/ml) had a relative risk of 
0.44 (0.26-0.75) of cancer compared to women in the lowest tertile (≤ 2.42 ng/ml) in the 
multivariable adjusted model (appendix table 1).  In men below 60 years of age (appendix 
table 1 the relative risk of cancer was 1.10 (95% CI 0.90-1.34) per 1 SD (0.99 ng/ml) increase 
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in serum OPG, whereas men in the upper tertile of serum OPG (≥ 2.87 ng/ml) had a relative 
risk of 1.48 (0.95-2.31) of cancer compared to men in the lowest tertile (≤ 2.33 ng/ml) in the 
adjusted model (appendix table 1).  No significant associations between serum OPG and risk 
of incident cancer were found in men and women above 60 years of age. 
To investigate whether serum OPG was associated with particular types of cancer, we 
performed stratified analyses for the most common types of cancer (table 4).  The relative risk 
of gastrointestinal cancers increased by 15% per 1 SD (1.12 ng/ml) increase in serum OPG, 
whereas those in the upper tertile of serum OPG (≥3.55 ng/ml) had 79% higher relative risk of 
cancer compared to subjects  in the lowest tertile (≤2.78 ng/ml) in the adjusted model.  The 
risk estimates were independent of age (appendix table 2).  The cumulative incidence rates for 
gastrointestinal cancer progressively diverged across tertiles of serum OPG over time. 
Probability curves of survival free of gastrointestinal cancer are shown in figure 1, panel A. 
Colorectal cancer comprised 59% (n=164) of the gastrointestinal cancers.  Subjects in the 
upper tertile of OPG had 49% higher relative risk of colorectal cancer compared to subjects in 
the lowest tertile (p for trend 0.087).  However, the strongest association between OPG and 
gastrointestinal cancer was found for esophagus (n=16), stomach (n=40) and pancreatic 
(n=39) cancer merged.  The relative risk increased by 37% per 1 SD increase in serum OPG 
and was 2.55 fold higher in tertile 3 compared to tertile 1 (95% CI; 1.23-5.30).  
An inverse association between serum OPG and risk of breast cancer was observed (women 
only) (Table 4 and appendix table 2).  The relative risk of breast cancer decreased by 26% per 
1 SD (1.06 ng/ml) increase in serum OPG, whereas women in the upper tertile of serum OPG 
(≥3.68 ng/ml) had 45% lower relative risk of breast cancer compared to women in the lowest 
tertile (<2.90 ng/ml) in the adjusted model. The cumulative incidence rates for breast cancer 
progressively diverged across tertiles of serum OPG over time. Probability curves of survival 
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free of breast cancer are shown in figure 1, panel B. In analyses stratified by age (appendix 
table 2), the protective effect of serum OPG on breast cancer applied to women below 60 
years of age.  The relative risk of breast cancer was 0.51 (95% CI 0.31-0.83) per 1 SD (0.81 
ng/ml) increase in serum OPG, and women in the upper tertile of serum OPG (≥3.08 ng/ml) 
had 76% reduced relative risk (0.24 (95% CI 0.10-0.61)) of breast cancer compared to women 
in the lowest tertile (<2.42 ng/ml) in this age group.     
 There were 387 subjects who died from cancer during follow up (median 12.6 years).  
The crude incidence rates of cancer-related mortality were 5.48 (95% CI 4.96-6.05) in the 
total population, 3.86 (95% CI 3.27- 4.55) in women and 7.22 (95% CI 6.37- 8.18) in men per 
1000 person-years, respectively. Serum OPG was associated with risk of cancer-related 
mortality irrespective of whether OPG was treated as a continuous or categorized variable 
(tertiles) (table 5).  The overall relative risk of cancer-related mortality increased by 25% per 
1 SD (1.12 ng/mL) increase in serum OPG, and subjects in the upper tertile of serum OPG 
had 63% higher relative risk of dying from cancer than those within the lowest tertile of 
serum OPG.  The cumulative incidence rates for cancer-related mortality progressively 
diverged across tertiles of serum OPG throughout the observation period. Probability curves 
of survival  are shown in figure 1, panel C.  The association between serum OPG and cancer-
related mortality was mostly driven by the relation to mortality from gastrointestinal cancers.  
The risk of dying from cancer in the gastrointestinal tract was 2.3 fold higher for subjects in 
the upper tertile of OPG compared to subjects in the lower tertile (p for trend=0.012).  In 
women, no significant associations between OPG and death of all cancers merged were 
observed (appendix table 3). OPG tended to be associated with death of gastrointestinal 
cancer in women (increased 39% per 1 SD OPG (95% CI; 1.06-1.83) and almost 2 fold higher 
relative risk in tertile 3 versus tertile 1 of OPG).  In contrast, in men a significant association 
between OPG and risk of dying of all cancers merged was observed, but no significant 
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association between OPG and risk of dying of gastrointestinal cancer was found (appendix 
table 3).  No significant association was observed between OPG levels and death from cancer 
in the respiratory system (table 5).  Death from prostatic cancer occurred for 1 in the lower 
tertile of OPG, 15 in the middle tertile and 20 men in the upper tertile.  However, no 
significant association was found (data not shown).  Seven women died from breast cancer 




The present population based cohort study showed for the first time that serum OPG was 
associated with cancer-related mortality in general. Subgroup analyses revealed that this 
association in women was mostly driven by the relation to mortality from gastrointestinal 
cancers.   However, serum OPG was not associated with risk of incident cancer in general, but 
displayed differential associations to gastrointestinal and breast cancer (women only). The 
relative risk of incident gastrointestinal cancer increased by 15% per SD increase in serum 
OPG, and subjects in the upper tertile of serum OPG had 79% higher relative risk than those 
in the lowest tertile.  Subgroup analyses showed significant associations between OPG and  
oesophagus, stomach and pancreas cancer merged with 2.5 fold increased HR for subjects in 
the upper tertile compared to tertile 1. Serum OPG was inversely associated with risk of 
breast cancer, particularly in women < 60 years. No significant associations were observed 
between OPG and incident respiratory cancer, urinary tract cancer, prostatic cancer or genital 
cancer (women).   
 
Although the potential impact of the OPG-RANKL-TRAIL axis on risk of cancer and cancer-
related mortality has been comprehensively studied in experimental models (5-15), few data 
are available from observational and interventional studies in humans.  Previously, we 
observed an association between serum OPG and mortality from non-vascular causes in the 
general population (HR 1.31, 95% CI 1.22-1.41) (16).  Similar risk estimates, although not 
statistical significant, for mortality from non-vascular events were reported from the Bruneck 
cohort study including 915 subjects from the general population (19).  The lack of significant 
associations in the Bruneck study between serum OPG and incident cancer  and cancer related 
mortality  may be due to low power caused by low number of events (n=146 and n=81, 




Our main finding that serum OPG was associated with risk of incident gastrointestinal cancers 
and mortality related to gastrointestinal cancers is supported by experimental and clinical 
studies. Increased expression of OPG has been reported in human gastric carcinoma (21) and 
colon cancer cell lines (22), as well as in patients with colorectal cancers and pancreatic 
cancers compared to healthy controls (23, 24). Addition of exogenous OPG to colorectal 
cancer cells caused resistance to TRAIL (23). Moreover, OPG mRNA expression was 
significantly higher in tumors with metastasis than without metastasis in both patients with 
gastric carcinoma (21) and colorectal cancer (25), and high expression of OPG was associated 
with decreased survival (21, 25) and increased risk of  recurrence (25).  Thus, our findings 
suggest that high serum OPG is an early biomarker of gastrointestinal cancers (more than a 
year ahead of diagnosis) and in women predicts mortality related to the disease.  
 
Even though serum OPG was associated with higher risk of gastrointestinal cancers in women 
as well as in men, younger women (< 60 years) showed an inverse relation between serum 
OPG and risk of incident total cancer. The inverse relation with total cancers in young women 
was mainly driven by incident breast cancer and cancer in the female genital organs.  
Experimental studies in breast cancer cells showed expression of OPG and inhibition of 
TRAIL induced apoptosis, suggesting that OPG may play a role in tumor cell survival (8).  
The expression of OPG in a large selection of breast tumors was also inversely correlated with 
tumor grade (8).  Synthetic progesterone derivatives, such as medroxyprogesterone acetate 
(MPA), induced RANKL in mammary-gland epithelial cells in mice (13).  Subsequent 
deletion of RANK from the mammary epithelium decreased incidence and delayed onset of 
MPA-driven mammary cancer (13).  Moreover, selective inhibition of RANKL reduced pre-
neoplasias as well as hormone- and carcinogen induced mammary epithelial proliferation 
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(14).   RANKL has also been shown to stimulate pulmonary metastasis of RANK(+) human 
breast cancer cells (15). Recently, it was shown in a mouse model for estrogen receptor-
positive breast cancer that RANKL inhibition by OPG-Fc treatment blocked osteoclast 
activity and prevented tumor-induced osteolysis.  In a combination experiment, OPG-Fc and 
tamoxifen resulted in a more efficient inhibition of tumor growth than either single agent 
alone (26).  Thus, it has been proposed that inhibition of RANKL-RANK signalling might be 
used in conjunction with elimination of primary breast tumors to prevent recurrent metastatic 
disease (15). Furthermore, microarray analysis of 295 primary breast cancer patients revealed 
that high OPG mRNA levels correlated with differentiated tumors and longer overall- and 
disease-free survival (27).  
In agreement with the animal models (13-15, 26), our population based study indicate that the 
cytokine network OPG is part of might also be important in development of tumors, and 
suggest that the inverse relation between serum OPG and risk of breast cancer, might be 
explained by reduced binding of RANKL to RANK in subjects with higher concentration of 
OPG.    
 
Among patients with prostatic cancer serum OPG levels were significantly elevated in 
patients with bone metastasis and predicted prostatic cancer related death (28).  In our 
population based cohorts study, 178 subjects developed prostatic cancer during follow up. We 
observed no significant association between OPG and incident prostatic cancer.  The 
relatively high number of events makes a type II error unlikely.   
 
In the present study, 167 subjects were diagnosed with cancer in the respiratory system and 
132 of them died from their cancer during the observation period.  No associations were 
observed between serum OPG and risk of cancer and cancer-related mortality in the 
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respiratory system.  In human non-small cell lung cancer (NSCLC) tissue samples, 
significantly stronger immunostaining for OPG, RANKL and RANK were observed in bone 
metastases than in tumor cells at the primary site (29).  Furthermore, the RANKL:OPG ratios 
were significantly higher in bone metastases compared with primary NSCLC tissue samples 
(29).  
 
The differential impact of OPG in various types of cancer might partly be explained by 
different significance of TRAIL induced apoptosis. For instance, many colorectal cancers 
show resistance to TRAIL partly due to expression of antagonistic decoy receptors (30).  The 
effect of OPG varies according to expression rates, spatial distribution of receptors, decoys 
and ligands (31). An epidemiological study will never be able to disentangle the important 
balance between local and systemic actions of cytokines. However, it is intriguing that serum 
concentrations of OPG, in the present population based study, years before cancer 
development are associated with gastrointestinal cancer and breast cancer.  The introduction 
of a monoclonal antibody (denosumab) to RANKL for the treatment of osteoporosis and 
reduction of skeletal events in subjects with breast cancer and prostatic cancer treated with 
hormones, underline the importance of further research.    
 
Major advantages of the present study includes the population-based design, high number of 
participants, long term follow-up and the completeness of end-point registration.  Some 
limitations also merit consideration. Despite the high number of participants, the number of 
subjects in some cancer groups was relatively low. Potential confounders and assumptions for 
statistical models were carefully checked, however potential residual confounding cannot be 
completely ruled out. It is uncertain whether our findings in a European Caucasian population 
are generalizable to other ethnical groups. OPG was measured only at one time point and 
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potentially our risk estimates could be somewhat underestimated due to regression dilution. 
Non- fasting blood samples and non-standardized time points for sampling could introduce 
bias.  In young normolipemic males the serum concentration of OPG decreased modestly 
during the day (32). In the postprandial state after a lipid rich meal we have found a similar 
modest decrease in serum OPG. Thus, it is unlikely that non-fasting blood samples and 
various time points for sampling during the day have introduced severe bias. Serum samples 
were kept frozen for 12 years at -70o C without any freezing-thawing cycles before 
measurement of OPG and this may have influenced the measurements.  However, previous 
studies have reported long-term stability of OPG measurements in serum samples stored at -
70° C (33).   
In conclusion, serum OPG was associated with incident cancer and death from cancer in the 
gastrointestinal system, and inversely associated with incident breast cancer in young women.  
Our findings support that OPG is a biomarker for development of certain cancers and that 










Legend to figure 
Figure 1  
Probability of survival free of: A; gastrointestinal cancer, B; breast cancer and C;  cancer 
related mortality stratified by OPG tertiles. Adjusted for age, sex, smoking, BMI, systolic 
blood pressure, HDL cholesterol, CRP, diabetes mellitus or HbA1c >6.1 %, ischemic stroke 
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